<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="62C666BB-262F-49FE-9B31-6AFA25A33392" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title mediaType="text/x-hl7-title+xml">Hydergine<sup>&#174;</sup></title>
<effectiveTime value="20060510" />
<setId root="62C666BB-262F-49FE-9B31-6AFA25A33392" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Novartis Pharmaceuticals Corporation</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="D20BCB89-F259-1C43-20CB-6EB68CCD1D6F" />
<effectiveTime value="20060510" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0078-0070" codeSystem="2.16.840.1.113883.6.69" />
<name>Hydergine</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="1">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="1" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="X3S33EX3KW" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>ergoloid mesylates</name>
<activeMoiety>
<activeMoiety>
<code code="X3S33EX3KW" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>ergoloid mesylates</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>ergoloid mesylates</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>povidone</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>stearic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>talc</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0078-0070-06" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43179" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX, UNIT-DOSE" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0078-0070-05" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator value="500">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="500" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0078-0070-08" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="8" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">HYDERGINE;1</value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="1" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="true" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE" />
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0078-0100" codeSystem="2.16.840.1.113883.6.69" />
<name>Hydergine</name>
<formCode code="C42953" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LIQUID" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="1">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="1" />
</numerator>
<denominator unit="mL" value="1">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="X3S33EX3KW" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>ergoloid mesylates</name>
<activeMoiety>
<activeMoiety>
<code code="X3S33EX3KW" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>ergoloid mesylates</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>ergoloid mesylates</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<quantity>
<numerator unit="mL" value="28.5">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="28.5" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<inactiveIngredientSubstance>
<code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>alcohol</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>glycerin</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>propylene glycol</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>purified water</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0078-0100-36" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0078-0101" codeSystem="2.16.840.1.113883.6.69" />
<name>Hydergine LC</name>
<formCode code="C42954" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE, LIQUID FILLED" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="1">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="1" />
</numerator>
<denominator value="1">
<translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="X3S33EX3KW" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>ergoloid mesylates</name>
<activeMoiety>
<activeMoiety>
<code code="X3S33EX3KW" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>ergoloid mesylates</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>ergoloid mesylates</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="PQ6CK8PD0R" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>ascorbic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>gelatin</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>glycerin</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>methylparaben</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>polyethylene glycol</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>propylene glycol</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>propylparaben</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sorbitol</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>titanium dioxide</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0078-0101-06" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43179" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX, UNIT-DOSE" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0078-0101-05" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator value="500">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="500" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0078-0101-08" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="11" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">HYDERGINE;LC;1;mg</value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="1" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="true" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"><originalText>off-white</originalText></value>
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section>
<id root="6E967D4D-A9FA-5E00-4A39-41F3D78FFB35" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml" />
<text><paragraph>T1999-75</paragraph><paragraph><content styleCode="bold">H</content><content styleCode="bold">y</content><content styleCode="bold">dergin</content><content styleCode="bold">e</content><sup>&#174;</sup></paragraph><paragraph><content styleCode="italics">(ergoloid mesylates</content><content styleCode="italics">) </content>Tablets, USP (ORAL)</paragraph><paragraph><content styleCode="italics">(ergoloid mesylates)</content> Liquid, USP</paragraph><paragraph><content styleCode="bold">H</content><content styleCode="bold">y</content><content styleCode="bold">dergin</content><content styleCode="bold">e</content><sup>&#174;</sup><content styleCode="bold">&#160;</content><content styleCode="bold">LC</content></paragraph><paragraph><content styleCode="italics">(ergoloid mesylates, USP)</content> Liquid Capsules</paragraph><paragraph><content styleCode="bold">Rx only</content></paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="7DCE1C4B-E3C8-4F9E-5C39-7B855BB73A28" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">DESCRIPTION</content></title>
<text />
<effectiveTime value="20060510" />
<component>
<section>
<id root="88288267-D542-FC47-106A-52E7906543BE" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Hydergine</content><content styleCode="bold"><sup>&#174;</sup></content><content styleCode="bold"> Tablet 1 mg and </content><content styleCode="bold"><br />Hydergine</content><content styleCode="bold"><sup>&#174;</sup></content><content styleCode="bold"> LC Liquid Capsule 1 mg</content></title>
<text><paragraph>Each contains ergoloid mesylates, USP as follows: dihydroergocornine mesylate 0.333 mg, dihydroergocristine mesylate 0.333 mg, and dihydroergocryptine (dihydro-alpha-ergocryptine and dihydro-beta-ergocryptine in the proportion of 2:1) mesylate 0.333 mg, representing a total of 1 mg.</paragraph><paragraph><content styleCode="italics">Inactive Ingredients</content></paragraph><paragraph><content styleCode="italics">Oral Tablets:</content> lactose, povidone, starch, stearic acid, and talc.</paragraph><paragraph><content styleCode="italics">Liquid Capsules:</content> ascorbic acid, gelatin, glycerin, methylparaben, polyethylene glycol, propylparaben, propylene glycol, sorbitol, and titanium dioxide.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="D527233F-EE81-0C8B-44D2-EF1BA2D34649" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Hydergine</content><content styleCode="bold"><sup>&#174;</sup></content><content styleCode="bold"> Liquid 1 mg/mL</content></title>
<text><paragraph>Each mL contains ergoloid mesylates, USP as follows: dihydroergocornine mesylate 0.333&#160;mg, dihydroergocristine mesylate 0.333&#160;mg, and dihydroergocryptine (dihydro-alpha-ergocryptine and dihydro-beta-ergocryptine in the proportion of 2:1) mesylate 0.333&#160;mg, representing a total of 1mg; alcohol, 28.5% by volume.</paragraph><paragraph><content styleCode="italics">Inactive Ingredients:</content> alcohol, glycerin, propylene glycol, and purified&#160;water.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="43BB7E17-2A4C-47D1-1CBF-89C4DC8ACC60" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Pharmacokinetic Properties</content></title>
<text><paragraph>Pharmacokinetic studies have been performed in normal volunteers with the help of radiolabelled drug as&#160;well&#160;as employing a specific radioimmunoassay technique. From the urinary excretion quotient of orally and intravenously administered tritium-labelled Hydergine<sup>&#174;</sup> (ergoloid mesylates) the absorption of ergoloid was calculated to be 25%. Following oral administration, peak levels of 0.5 ngEq/mL/mg were achieved within 1.5-3 hr. Bioavailability studies with the specific radioimmunoassay confirm that ergoloid is rapidly absorbed&#160;from the gastrointestinal tract, with mean peak levels of 0.05-0.13&#160;ng/mL/mg (with extremes of 0.03 and 0.18 ng/mL/mg) achieved within 0.6-1.3 hr (with extremes of 0.4 and 2.8 hr). The finding of lower peak levels of ergoloid compared to the total drug-metabolite composite is consistent with a considerable first pass liver metabolism, with less than 50% of the therapeutic moiety reaching the systemic circulation. The elimination of radioactivity, representing ergoloid plus metabolites bearing the radiolabel, was biphasic with half-lives of 4 and 13 hr. The mean half-life of&#160;unchanged ergoloid in plasma is about 2.6-5.1 hr; after 3&#160;half-lives ergoloid plasma levels are less than 10% of radioactivity levels, and by 24 hr no ergoloid is detectable.</paragraph><paragraph>Bioequivalence studies were performed comparing Hydergine<sup>&#174;</sup> (ergoloid mesylates) oral tablets (administered orally) with Hydergine<sup>&#174;</sup> (ergoloid mesylates) sublingual tablets (administered sublingually), Hydergine<sup>&#174;</sup> (ergoloid mesylates) oral tablets with Hydergine<sup>&#174;</sup> (ergoloid mesylates) liquid, and Hydergine<sup>&#174;</sup> (ergoloid mesylates) oral tablets with Hydergine<sup>&#174;</sup>&#160;LC (ergoloid mesylates, USP) liquid capsules. The oral tablet, sublingual tablet, and liquid capsule oral forms were shown to be bioequivalent. Within the bioequivalence limits, the liquid capsule showed a statistically significant (12%) greater bioavailability than the oral tablet. In the study comparing the oral tablet and liquid forms, both forms tested showed an equivalent rate of absorption and an equivalent peak plasma concentration (C<sub>max</sub>).</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="692D6647-1FFA-FBAC-006A-895AE93228D3" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">ACTIONS</content></title>
<text><paragraph>There is no specific evidence which clearly establishes the mechanism by which Hydergine<sup>&#174;</sup> (ergoloid mesylates) preparations produce mental effects, nor is there conclusive evidence that the drug particularly affects cerebral arteriosclerosis or cerebrovascular insufficiency.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="C39E2FAC-19BE-F15B-3752-65A778A21474" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS AND USAGE SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">INDICATIONS</content></title>
<text><paragraph>A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with Hydergine<sup>&#174;</sup> (ergoloid mesylates) preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to Hydergine<sup>&#174;</sup> (ergoloid mesylates) therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to&#160;aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer&#8217;s dementia, senile onset, multi-infarct dementia).</paragraph><paragraph>Before prescribing Hydergine<sup>&#174;</sup> (ergoloid mesylates), the physician should exclude the possibility that the patient&#8217;s signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to&#160;exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Hydergine<sup>&#174;</sup> (ergoloid mesylates) preparations are not indicated in the treatment of acute or&#160;chronic psychosis, regardless of etiology <content styleCode="italics">(see CONTRAINDICATIONS).</content></paragraph><paragraph>The decision to use Hydergine<sup>&#174;</sup> (ergoloid mesylates) in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a&#160;specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by Hydergine<sup>&#174;</sup> (ergoloid mesylates) therapy persists with time.</paragraph><paragraph>The efficacy of Hydergine<sup>&#174;</sup> (ergoloid mesylates) was evaluated using&#160;a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end&#160;of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="2F909235-53D9-7B10-A788-4CFDBB62B9DE" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">CONTRAINDICATIONS</content></title>
<text><paragraph>Hydergine<sup>&#174;</sup> (ergoloid mesylates) preparations are contraindicated in individuals who have previously shown hypersensitivity to the drug. Hydergine<sup>&#174;</sup> (ergoloid mesylates) preparations are also contraindicated in patients who have psychosis, acute or chronic, regardless of etiology.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="BE5D58B8-25A6-EDEA-D93C-A4EE18873DF3" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">PRECAUTIONS</content></title>
<text><paragraph><content styleCode="italics">Practitioners are advised that because the target symptoms are of unknown etiology, careful diagnosis should be attempted before prescribing Hydergine</content><content styleCode="italics"><sup>&#174;</sup></content><content styleCode="italics"> (ergoloid mesylates) preparations.</content></paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="BB57E6CD-2771-0651-132D-A5F900DB754A" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">ADVERSE REACTIONS</content></title>
<text><paragraph>Hydergine<sup>&#174;</sup> (ergoloid mesylates) preparations have not been found to produce serious side effects. Transient nausea and gastric disturbances have been reported. Hydergine<sup>&#174;</sup> (ergoloid mesylates) preparations do not possess the vasoconstrictor properties of the natural ergot alkaloids.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="897323E2-CC64-07C1-1CDB-76A0367145BA" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">DOSAGE AND ADMINISTRATION</content></title>
<text><paragraph>1 mg three times daily.</paragraph><paragraph>Alleviation of symptoms is usually gradual and results may not be observed for 3-4 weeks.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="F2C4B0FA-074D-FBFB-E992-1887BB3F7354" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">HOW SUPPLIED</content></title>
<text />
<effectiveTime value="20060510" />
<component>
<observationMedia ID="MM02000002">
<value mediaType="image/jpeg" xsi:type="ED"><reference value="hydergine-figure-02.jpg" /></value>
</observationMedia>
</component>
<component>
<section>
<id root="F5CC93D3-151E-9BB8-A0DE-1BFBB45AA02C" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Hydergine</content><content styleCode="bold"><sup>&#174;</sup></content><content styleCode="bold"> (ergoloid mesylates) Tablets, USP (Oral)</content></title>
<text />
<effectiveTime value="20060510" />
<component>
<section>
<id root="6248F838-A671-02E4-7FBC-2B60CDCA0FF4" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold italics">1&#160;mg</content></title>
<text><paragraph>Round, white, engraved &#8220;HYDERGINE 1&#8221; on one side, &#8220;<renderMultiMedia referencedObject="MM02000002" />&#8221; other&#160;side.</paragraph><paragraph>NDC 0078-0070-05: bottles of 100</paragraph><paragraph>NDC 0078-0070-06: unit-dose packages of 100</paragraph><paragraph>NDC 0078-0070-08: bottles of 500</paragraph></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="BF5DB356-5BDA-F8E5-7865-D10530A42284" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold italics">Store and Dispense</content></title>
<text><paragraph>Below 77&#176;F (25&#176;C); tight, light-resistant container.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section>
<id root="D2442B7D-7113-2CE2-E738-5E1F9132BA2A" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Hydergine</content><content styleCode="bold"><sup>&#174;</sup></content><content styleCode="bold"> (ergoloid mesylates) Liquid, USP </content></title>
<text />
<effectiveTime value="20060510" />
<component>
<section>
<id root="DBFC5972-5EAF-E9CD-7DAB-DEE13352D02C" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold italics">1 mg/mL</content></title>
<text><paragraph>Supplied with an accompanying dropper graduated to deliver 1 mg.</paragraph><paragraph>NDC 0078-0100-36: bottles of 100 mL</paragraph></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="F2C3CCFA-779B-EE57-83AF-5E2FAFF4AF7C" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold italics">Store and Dispense</content></title>
<text><paragraph>Below 86&#176;F (30&#176;C); tight, amber glass bottle.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section>
<id root="64945482-A2FF-E069-EF64-209054F140DF" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Hydergine</content><content styleCode="bold"><sup>&#174;</sup></content><content styleCode="bold"> LC (ergoloid mesylates, USP) Liquid Capsule</content></title>
<text />
<effectiveTime value="20060510" />
<component>
<section>
<id root="6F7EE9C0-B4B2-3D0F-9BE5-453537348DA7" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold italics">1 mg</content></title>
<text><paragraph>Oblong, off-white, branded &#8220;HYDERGINE LC 1 mg&#8221;</paragraph><paragraph>on one side, &#8220;<renderMultiMedia referencedObject="MM02000002" />&#8221; other side.</paragraph><paragraph>NDC 0078-0101-05: bottles of 100</paragraph><paragraph>NDC 0078-0101-06: unit-dose packages of 100</paragraph><paragraph>NDC 0078-0101-08: bottles of 500</paragraph></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="6F9FA82D-0DBF-439F-8A44-1D706243E9DC" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold italics">Store and Dispense</content></title>
<text><paragraph>Between 59&#176; and 77&#176;F (15&#176; and 25&#176;C); tight, light-resistant container. DO NOT FREEZE.</paragraph><paragraph>(Encapsulated by R. P. Scherer, N.A., Clearwater, Florida 33518)</paragraph><paragraph /><paragraph>Tablets manufactured by:</paragraph><paragraph>Novartis Pharmaceuticals Canada Inc</paragraph><paragraph>Dorval (Quebec), Canada H9S 1A9</paragraph><paragraph>Distributed by:</paragraph><paragraph>Novartis Pharmaceuticals Corporation</paragraph><paragraph>East Hanover, New Jersey 07936</paragraph><paragraph /><paragraph>T1999-75</paragraph><paragraph /><paragraph>&#169;1999 Novartis</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
</section>
</component>
</section>
</component>
</structuredBody>
</component>
</document>
